Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/Smad and GRAP pathways

Area of Science:

• Nephrology
• Pharmacology
• Molecular Biology

Background:

• Diabetic nephropathy is a major complication of diabetes, characterized by kidney damage.
• The transforming growth factor-beta 1 (TGF-β1)/Smad pathway plays a critical role in the pathogenesis of diabetic nephropathy.
• GRAP protein expression is altered in diabetic kidney disease.

Purpose of the Study:

• To investigate the renoprotective effects of ruboxistaurin, a selective protein kinase C-beta (PKC-β) inhibitor.
• To determine if ruboxistaurin interferes with TGF-β1/Smad-GRAP cross-signalling in diabetic nephropathy.

Main Methods:

• Diabetes was induced in rats using streptozotocin.
• Diabetic rats were treated with ruboxistaurin (10 mg/kg) or valsartan (positive control) for 6 weeks.
• Renal function biomarkers, and TGF-β1, Smad2, Smad3, and GRAP mRNA and protein levels were assessed using qPCR and western blot.

Main Results:

• Ruboxistaurin treatment significantly attenuated increased serum creatinine, kidney/body weight ratio, and urinary albumin excretion in diabetic rats.
• Ruboxistaurin administration alleviated the up-regulation of TGF-β1, Smad2, and Smad3 mRNA and protein levels.
• Treatment with ruboxistaurin prevented the reduction in GRAP protein expression in diabetic kidneys.

Conclusions:

• Ruboxistaurin exhibits renoprotective effects in diabetic nephropathy.
• These protective effects are likely mediated by the down-regulation of the TGF-β1/Smad pathway.
• Ruboxistaurin also normalizes GRAP protein expression, contributing to its renoprotective action.